sur HBM Healthcare Investments AG (isin : CH0012627250)
HBM Healthcare Investments' Swixx BioPharma Boosts Sales through Latin American Acquisition
Swixx BioPharma, a significant holding in HBM Healthcare Investments' private equity portfolio, has announced its strategic expansion into Latin America by acquiring the Laboratorios Biopas Group. This acquisition is expected to enhance Swixx BioPharma's sales and profits.
Biopas, with $220 million in sales and over 300 employees, is a leading marketing and distribution company in Latin America, covering markets such as Argentina, Brazil, Chile, Colombia, and Mexico. The deal will enable Swixx to increase its therapeutic coverage in Neurology, Oncology, Gastroenterology, and Rare Diseases.
This move follows Swixx's entry into the Middle East in 2023. Financing for the acquisition will come from a mix of cash, bank loans, and equity, with regulatory approval anticipated by mid-2024. HBM Healthcare Investments holds a 25% stake in Swixx BioPharma.
R. E.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de HBM Healthcare Investments AG